Abaloparatide: Tymlos bone-building osteoporosis drug
A lab-made injectable drug that stimulates the body to build new bone, used to treat osteoporosis in people at high risk of fractures; FDA-approved.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Abaloparatide (brand name Tymlos) is an FDA-approved injectable medication used to treat osteoporosis — a condition in which bones become thin and fragile, leading to fractures. It belongs to a class of drugs called osteoanabolics, meaning it actively stimulates the body to build new bone rather than just slowing bone loss. Abaloparatide is a synthetic 36-residue peptide designed from the N-terminal region of parathyroid hormone-related protein (PTHrP), a natural hormone involved in bone and calcium regulation. It was approved by the FDA in April 2017 for postmenopausal women with osteoporosis at high risk of fracture, and a subsequent approval extended the indication to men with osteoporosis.
History
The origins of abaloparatide trace back to the discovery of PTHrP in the 1980s as the molecule responsible for humoral hypercalcemia of malignancy — a condition in which certain cancers release a hormone-like factor that causes dangerously elevated calcium levels. PTHrP was found to share significant structural homology with parathyroid hormone (PTH) at the N-terminus and to act on the same receptor (PTH1R), but with distinct physiological roles in bone development, cartilage, and lactational calcium metabolism.
The therapeutic hypothesis pursued by Radius Health was that targeted substitutions in the PTHrP 1–34 sequence could engineer preferential binding to a specific receptor conformation — the so-called RG state — to produce a cleaner anabolic effect than existing PTH analogs. Hattersley and colleagues (Endocrinology 2016) characterized this binding selectivity in detail, showing that abaloparatide engages the RG conformation of PTH1R more preferentially than PTH 1-34, which produces a more transient intracellular signaling response. The pivotal Phase 3 ACTIVE trial results were reported by Miller and colleagues in JAMA in 2016, and the FDA granted approval on April 28, 2017. The original label carried a boxed warning for osteosarcoma risk — derived from rat carcinogenicity studies shared with the teriparatide class — as well as a cumulative lifetime use restriction; the FDA removed both in 2022 following accumulated post-marketing data showing no human osteosarcoma signal. The ACTIVExtend trial (Cosman and colleagues, Mayo Clinic Proceedings 2017) subsequently established the sequential treatment paradigm: abaloparatide for the anabolic phase followed by an antiresorptive agent to consolidate gains. The ATOM trial later demonstrated efficacy and safety in men with osteoporosis, leading to the expanded indication.
What it does
Abaloparatide tells bone-building cells (osteoblasts) to increase their activity, shifting the balance of bone remodeling toward formation. Given once daily, it produces a pulsatile signal at the PTH1 receptor that favors new bone synthesis over bone breakdown — the opposite of what happens with continuous PTH1R activation (as in primary hyperparathyroidism, which is catabolic). The practical result, demonstrated in clinical trials, is measurable increases in bone mineral density at the spine, hip, and femoral neck, and a significant reduction in the risk of vertebral and non-vertebral fractures in people with osteoporosis. Because abaloparatide's anabolic effect depends on the once-daily pulsatile schedule, the gains begin to reverse after discontinuation unless an antiresorptive medication (such as a bisphosphonate) is started to consolidate the newly built bone.
Evidence
- Human: Strong. The Phase 3 ACTIVE trial (Miller and colleagues, JAMA 2016) randomized 2,463 postmenopausal women at high fracture risk to abaloparatide, open-label teriparatide, or placebo for 18 months; abaloparatide significantly reduced new morphometric vertebral fractures and non-vertebral fractures versus placebo, with bone mineral density gains at the lumbar spine, total hip, and femoral neck that were comparable to or greater than teriparatide, alongside a lower rate of treatment-emergent hypercalcemia. The ACTIVExtend trial (Leder and colleagues, Journal of Bone and Mineral Research 2019) showed that patients who transitioned from abaloparatide to alendronate preserved and extended fracture-risk reduction over an additional period. The ATOM trial established comparable efficacy and safety in men with osteoporosis. A 2025 network meta-analysis (Höppner and colleagues, Nature Communications) and multiple systematic reviews and Bayesian network meta-analyses confirm the fracture-risk reduction and BMD gains in postmenopausal women; a 2025 network meta-analysis in Frontiers in Endocrinology addressed the male osteoporosis indication.
- Animal: Extensive. Ovariectomized-rat and orchiectomized-rat models, as well as disuse and glucocorticoid models, characterize abaloparatide's anabolic effects and receptor pharmacology, including bone histomorphometry data from the ACTIVE trial's biopsy substudy (Moreira and colleagues, Bone 2016).
- In vitro / mechanistic: Sato and colleagues (JBMR Plus 2021) compared intracellular signaling kinetics of abaloparatide, teriparatide, and long-acting PTH at PTH1R, providing mechanistic context for their distinct clinical profiles. The RG-conformation selectivity story is further elaborated in Leder's review (Current Osteoporosis Reports 2017).
Known effects
- Reduced vertebral fracture risk — FDA-approved (Phase 3, ACTIVE trial)
- Reduced non-vertebral fracture risk — FDA-approved (Phase 3, ACTIVE trial)
- Increased bone mineral density at lumbar spine, total hip, and femoral neck — FDA-approved (Phase 3, ACTIVE trial; ACTIVExtend follow-on)
- Treatment of osteoporosis in men — FDA-approved (ATOM trial)
- Sequential anabolic-antiresorptive therapy — supported by ACTIVExtend: transitioning to alendronate after abaloparatide preserves and extends fracture-risk reduction
Safety signals
Adverse events reported in the ACTIVE trial include injection-site reactions, dizziness and orthostatic hypotension (particularly after the first dose), nausea, palpitations, and transient hypercalcemia. Treatment-emergent hypercalcemia occurred at a lower rate with abaloparatide than with the open-label teriparatide comparator in ACTIVE (Miller and colleagues, JAMA 2016), consistent with the proposed RG-conformation selectivity mechanism. A dedicated cardiovascular safety analysis of ACTIVE (reported separately) found no increase in serious cardiac events. Abaloparatide shares the PTH1R-agonist class cautions: the drug is not indicated in patients with conditions associated with elevated baseline osteosarcoma risk (Paget's disease of bone, prior skeletal radiation, open epiphyses, unexplained elevated alkaline phosphatase) and should be used with caution in severe renal impairment. The original boxed warning for osteosarcoma risk — which was based on Fischer 344 rat carcinogenicity data and was never grounded in a human signal — was removed by the FDA in 2022, in parallel with the equivalent action on teriparatide, following post-marketing surveillance showing no osteosarcoma cases attributable to PTH1R agonists.
Regulatory status
- US: Prescription-only. FDA-approved (April 28, 2017) for postmenopausal women with osteoporosis at high risk of fracture; indication subsequently expanded to men with osteoporosis. Boxed warning and cumulative lifetime use cap removed by FDA in 2022. Marketed as Tymlos.
- Canada: Approved by Health Canada.
- UK: MHRA approval obtained in 2022.
- EU: The EMA's initial CHMP opinion in 2018 was negative; the original EU marketing authorization application was withdrawn. Access in EU member states has varied by country.
- Japan: Approved; Phase 3 data in Japanese patients (ACTIVE-J) are available.
- WADA: Abaloparatide is not specifically listed on the current WADA Prohibited List, but its anabolic bone activity and PTH1R-axis pharmacology would draw scrutiny in performance contexts; athletes with documented osteoporosis may use it under appropriate therapeutic use exemption documentation.
Myths and misconceptions
- "Abaloparatide is just a generic or biosimilar version of teriparatide." — It is a distinct molecule. Teriparatide is a synthetic copy of human PTH 1–34; abaloparatide is an engineered analog of PTHrP 1–34, a related but different hormone. It has its own sequence, receptor pharmacology (RG-conformation selectivity), pen device, and regulatory history. It is a brand-name drug (Tymlos), not a generic.
- "The boxed warning means abaloparatide causes bone cancer." — The original boxed warning came from rat carcinogenicity studies at high lifetime exposures — the same rat data that triggered the original teriparatide warning. Over five years of post-marketing surveillance after the 2017 US approval identified no human osteosarcoma cases, and the FDA removed the warning in 2022. Patients with conditions that already elevate osteosarcoma risk (Paget's disease, prior bone radiation, open epiphyses) remain a labeled caution.
- "Building bone with abaloparatide means the gains are permanent." — BMD gains are rapidly lost after discontinuation unless an antiresorptive agent is started to consolidate them. The ACTIVExtend trial was designed specifically to demonstrate the value of sequential therapy: the anabolic phase with abaloparatide, followed by alendronate, preserved and extended fracture-risk reduction beyond what abaloparatide alone achieves.
Mechanism
Abaloparatide binds and activates PTH1R (the parathyroid hormone type 1 receptor) on osteoblasts and their precursors. The key pharmacological distinction from teriparatide (PTH 1-34) is conformational selectivity: abaloparatide preferentially engages the RG conformation of PTH1R — a receptor state associated with more transient cAMP/PKA signaling — whereas PTH 1-34 binds more readily to both the RG and R0 (prolonged signaling) conformations. This conformational preference was characterized by Hattersley and colleagues (Endocrinology 2016) and elaborated in comparisons by Sato and colleagues (JBMR Plus 2021). The hypothesis is that more transient PTH1R activation drives a wider anabolic window — more net osteoblast activity relative to osteoclast stimulation — and produces less sustained hypercalcemia than PTH 1-34, both of which are directionally supported by the ACTIVE trial data.
Downstream signaling from pulsatile PTH1R activation suppresses sclerostin, activates the Wnt/β-catenin pathway, and promotes osteoblast proliferation, differentiation, and survival. The pulsatile once-daily schedule is mechanistically essential: continuous PTH1R stimulation drives net bone resorption rather than formation (as seen in primary hyperparathyroidism), so the pharmacology is schedule-dependent.
The raw stored sequence (AVSEHQLLHDKGKSIQDLRRRELLEKLLAKNLGPHR, 36 residues) represents the primary peptide chain of the synthetic analog; abaloparatide does not carry lipid or polymer conjugates, so no modifications are absent from the linear sequence.
Open questions
- Head-to-head fracture endpoint data versus teriparatide and romosozumab remain limited; the ACTIVE comparison was open-label for teriparatide only, and indirect network meta-analyses have methodological caveats (Leder, Current Osteoporosis Reports 2017; network meta-analyses 2025).
- Optimal sequencing within the expanded osteoanabolic toolkit — three anabolic agents are now FDA-approved (teriparatide, abaloparatide, romosozumab) — is still being worked through by guideline bodies.
- A transdermal microneedle-patch formulation (abaloparatide-sMTS) did not meet non-inferiority versus subcutaneous injection in Phase 3 trials; whether further device development can close the gap is unresolved.
- Abaloparatide has not been studied for glucocorticoid-induced osteoporosis to the degree teriparatide has, leaving a gap in the evidence base for this common indication.
- Repeat-course efficacy — whether a second treatment course after antiresorptive consolidation delivers additional benefit — has not been adequately studied.
Related peptides
Abaloparatide acts at the same PTH1 receptor as teriparatide (synthetic PTH 1–34), the first FDA-approved osteoanabolic peptide, and the two are frequently compared in clinical practice and meta-analyses (Leder and colleagues, Journal of Bone and Mineral Research 2019). Romosozumab, a sclerostin-inhibiting monoclonal antibody, represents a third FDA-approved osteoanabolic mechanism and sits alongside both peptides in current osteoporosis guidelines. Parathyroid hormone-related protein (PTHrP), the endogenous precursor whose N-terminal sequence provided the template for abaloparatide's design, plays roles in lactational calcium mobilization, vascular smooth muscle, and skeletal development distinct from PTH's primary calcium-regulatory role.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could abaloparatide replace missing parathyroid hormone in patients with underactive parathyroid glands more safely than existing options, by causing less kidney calcium loss?
People with hypoparathyroidism must take calcium and vitamin D every day for life, often with side effects affecting the kidneys. A safer hormone replacement that maintains calcium without damaging the kidneys would improve long-term health outcomes for thousands of patients.
Do the three consecutive arginine residues in abaloparatide cause the drug to stick to negatively charged molecules in bone before it even reaches the receptor, giving bone tissue a higher effective dose than kidney?
If bone matrix pre-concentrates abaloparatide, drug designers could amplify this effect by adding or optimizing the basic cluster to make an even more bone-targeted version, possibly achieving greater fracture reduction at a lower total dose with reduced kidney effects.
If the three positively charged arginines in abaloparatide cause it to stick non-specifically to tissues and clear too fast, could replacing them with a single modified amino acid extend its duration in the bloodstream?
Abaloparatide currently requires a daily injection, which is a major barrier to long-term use. A version that stays active for a week would dramatically improve patient adherence and potentially help more people maintain bone density and avoid fractures.
Is the C-terminal portion of abaloparatide mostly unstructured when it binds its receptor, and does this explain why it preferentially stimulates bone-building over calcium release?
If only the front of the drug locks onto the receptor while the back half remains loose, engineers could redesign the back half to create an even more selective bone builder with fewer side effects related to calcium metabolism.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.8326408863067627 | openfold3-mlx |
| ranking score | 0.9470502138137817 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.813 | global PDE — lower = better |
| disorder | 0.297 | fraction disordered |
| chain pair ipTM (A, B) | 0.833 | interface quality |
▸3-letter notation
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | — |
| hardware | — |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | — |
| diffusion samples | 1 |
| runtime | 837s |
| predicted by | mlx@peptide |
| predicted at | 2026-05-03 |
▸citationbibtex
@peptide{pep10975,
sequence = {AVSEHQLLHDKGKSIQDLRRRELLEKLLAKNLGPHR},
target = {pth1r},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}